# Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

> **NCT06987916** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Tongji Hospital, Tongji University School of Medicine** · enrollment: 50 (estimated)

## Conditions studied

- B Cell Lymphoma

## Interventions

- **BIOLOGICAL:** ssCART-19

## Key facts

- **NCT ID:** NCT06987916
- **Lead sponsor:** Shanghai Tongji Hospital, Tongji University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-22
- **Primary completion:** 2028-04-22
- **Final completion:** 2030-04-22
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06987916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06987916, "Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06987916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*